Hepatoprotective effects of empagliflozin in the treatment of patients with type 2 diabetes

Czech version

Authors: Peter Galajda; Marián Mokáň
Authors‘ workplace: I. interná klinika JLF UK a UNM, Martin
Published in: Forum Diab 2025; 14(2): 124-129
Category: Review Article

Overview

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, gliflozins are a modern and preferred class of diabetic medications in the treatment of patients with type 2 diabetes mellitus with important cardioprotective and nephroprotective benefit. Treatment with gliflozine has beneficial effect for every components of cardiovascular-kidney-liver-metabolic syndrome. In experimental studies using of SGLT-2 inhibitors is associated with reduction of hepatic fat due to inhibition of genes for lipogenesis de novo and activation of genes for fatty acid oxidation. Signs of steatohepatitis are reduced due to immunomodulative antiinflammatory effects of gliflozines. In clinical studies with empagliflozin in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease was confirmed beneficial effect for reduction of hepatic fat and FIB-4 index together with decreased transaminase activity.

Keywords:

type 2 diabetes mellitus – empagliflozin – cardiovascular-kidney-liver-metabolic syndrome – hepatoprotective benefit – metabolic dysfunction–associated steatotic liver disease – sodium-glucose cotransporter 2 (SGLT2) inhibitors

Sources

Martinka E, Mokáň M, Rašlová K et al. Interdisciplinárne štandardy diagnostiky a liečby diabetes mellitus, jeho komplikácií a najvýznamnejších sprievodných ochorení –⁠ 2021. Forum Diab 2021; 10(S2): 4–279.

[American Diabetes Association]. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes –⁠ 2025. Diabetes Care 2025; 48(Suppl.1): S59-S85. Dostupné z DOI: <http://dx.doi.org/10.2337/dc25-S004>.

Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78(6): 1966–1986. Dostupné z DOI: <http://dx.doi.org/10.1097/HEP.0000000000000520>.

Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022; 10(4): 284–296. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(22)00003–1>.

Younossi ZM, Golabi P, Price JK et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 2024; 22(10): 1999–2010. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2024.03.006>.

Cusi K, Isaacs S, Barb D et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28(5): 528–562. Dostupné z DOI: <http://dx.doi.org/10.1016/j.eprac.2022.03.010>.

Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol 2017; 112(1): 18–35. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2016.517>.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77(5): 1797–1835. Dostupné z DOI: <http://dx.doi.org/10.1097/HEP.0000000000000323>.

Siddiqui MS, Yamada G, Vuppalanchi R et al. [NASH Clinical Research Network]. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol 2019; 17(9): 1877–1885. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2018.12.031>.

[European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL)]. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024; 81(3): 492–542. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2024.04.031>.

Eddowes PJ, Sasso M, Allison M et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019; 156(6): 1717–1730. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2019.01.042>.

Mozes FE, Lee JA, Selvaraj EA et al. [LITMUS Investigators]. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022; 71(5): 1006–1019. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2021–324243>.

Saarinen K, Färkkilä M, Jula A et al. Enhanced liver fibrosis test predicts liver-related outcomes in the general population. JHEP Rep 2023; 5(7): 100765. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhepr.2023.100765>.

Andersson A, Kelly M, Imajo K et al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin Gastroenterol Hepatol 2022; 20(11): 2451–2461.e3. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2021.09.041>.

Armstrong MJ, Gaunt P, Aithal GP et al. [LEAN Trial Team]. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo controlled phase 2 study. Lancet 2016; 387(10019): 679–690. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00803-X>.

Newsome PN, Buchholtz K, Cusi K et al. [NN9931–4296 Investigators]. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384(12): 1113–1124. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2028395>.

Bandyopadhyay S, Das S, Samajdar SS et al. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Diabetes Metab Syndr 2023; 17(10): 102849. Dostupné z DOI: <http://dx.doi.org/10.1016/j.dsx.2023.102849>.

18. Zhu K, Kakkar R, Chahal D et al. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327–5338. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v29.i37.5327>.

Newsome PN, Sanyal AJ, Engebretsen KA et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: Baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther 2024; 60(11–12): 1525–1533. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.18331>.

Loomba R, Hartman ML, Lawitz EJ et al. [SYNERGY-NASH Investigators]. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024; 391(4): 299–310. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2401943>.

Sanyal AJ, Bedossa P, Fraessdorf M et al. [1404–0043 Trial Investigators]. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 2024; 391(4): 311–319. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2401755>.

Galajda P, Samoš M, Bolek T et al. Dlhodobé protektívne účinky empagliflozínu v celom spektre pacientov s diabetes mellitus 2. typu už od skorých štádií ochorenia. Forum Diab 2024; 13(1): 31–36.

Cooper J, Patel P, Tristeza J et al. Metabolic-associated steatotic liver disease: From molecular mechanisms to novel therapies. Int J Hepatol 2025; 2025 : 5580454. Dostupné z DOI: <http://dx.doi.org/10.1155/ijh/5580454>.

Sattar N, Fitchett D, Hantel S et al. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia 2018; 61(10): 2155–2163. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4702–3>.

Kuchay MS, Krishan S, Mishra SK et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care 2018; 41(8): 1801–1808. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–0165>.

Elhini SH, Wahsh EA, Elberry AA et al. The Impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals (Basel) 2022; 15(12): 1516. Dostupné z DOI: <http://dx.doi.org/10.3390/ph15121516>.

Cheung KS, Ng HY, Hui RWH et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Hepatology 2024; 80(4): 916–927. Dostupné z DOI: <http://dx.doi.org/10.1097/HEP.0000000000000855>.

Tang X, Zhang H, Wang X et al. Empagliflozin for the treatment of non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Afr Health Sci 2022; 22(3): 391–398. Dostupné z DOI: <http://dx.doi.org/10.4314/ahs.v22i3.42>.

Zhang Y, Liu X, Zhang H et al. Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022; 13 : 836455. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2022.836455>.

Lai LL, Vethakkan SR, Mustapha NR et al. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 2020; 65(2): 623–631. Dostupné z DOI: <http://dx.doi.org/10.1007/s10620–019–5477–1>.

Androutsakos T, Nasiri-Ansari N, Bakasis AD et al. SGLT-2 Inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci 2022; 23(6): 3107. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms23063107>.

Bendotti G, Montefusco L, Pastore I et al. The anti-inflammatory and immunological properties of SGLT-2 inhibitors. J Endocrinol Invest 2023; 46(12): 2445–2452. Dostupné z DOI: <http://dx.doi.org/10.1007/s40618–023–02162–9>.

Mazzieri A, Basta G, Calafiore R et al. GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway. Front Immunol 2023; 14 : 1163288. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2023.1163288>.

Gu Y, Sun L, Zhang W et al. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol 2023; 14 : 1102792. Dostupné z DOI: <http://dx.doi.org/.3389/fphar.2023.1102792>.

Lin YH, Zhang ZJ, Zhong JQ et al. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial. PLoS One 2024; 19(5): e0302155. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0302155>.